NASDAQ:KMDAKamada Stock Price, Forecast & News

$7.63

+0.08 (+1.06 %)

(As of 06/2/2020 03:46 PM ET)

Add

Compare

Today's Range

$7.50

Now: $7.63▼

$7.66

50-Day Range

$6.45

MA: $7.42▼

$8.58

52-Week Range

$4.40

Now: $7.63▼

$9.75

Volume1,715 shs

Average Volume127,044 shs

Market Capitalization$339.69 million

P/E Ratio14.13

Dividend YieldN/A

Beta1.25

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus, as well as human transferrin that is used as a cultural medium for diagnostic assays and cell cultures. In addition, Kamada Ltd. provides Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. Its products in pipeline are G1-AAT (IV) for graft versus host disease and L1-AAT (1V) for lung transparent, which are in Phase II stage; and D1-AAT (IV) for type-1 diabetes, Inhaled AAT for AAT deficiency, and AAT (liquid) for lung preservation and recombinant AAT, which are in early stage development. Further, the company distributes respiratory products, including Bramitob to manage chronic pulmonary infection and FOSTER for the treatment of asthma; and immunoglobulins comprising IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for prevention of hepatitis B virus; and Megalotect, a CMV immunoglobulin. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion S.p.A. Kamada Ltd. was founded in 1990 and is headquartered in Rehovot, Israel.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Kamada has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, Kamada has a potential upside of 44.2% from its current price of $7.63.
Amount of Analyst Coverage
Kamada has only been the subject of 1 research reports in the past 90 days.

2.2 Community Rank

Outperform Votes
Kamada has received 228 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Kamada has received 280 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Kamada has received 55.12% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote “Outperform” if you believe KMDA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KMDA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Kamada does not currently pay a dividend.
Dividend Growth
Kamada does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kamada insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 12.91% of the stock of Kamada is held by institutions.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Kamada are expected to decrease in the coming year, from $0.32 to ($0.04) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kamada is 14.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 15.73.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kamada is 14.13, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.36.
Price to Book Value per Share Ratio
Kamada has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.39 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:KMDA

Previous Symbol

CUSIPN/A

CIK1567529

Webwww.kamada.com

Phone972-8940-6472

Debt

Debt-to-Equity RatioN/A

Current Ratio6.55

Quick Ratio4.91

Price-To-Earnings

Trailing P/E Ratio14.13

Forward P/E Ratio23.84

P/E GrowthN/A

Sales & Book Value

Annual Sales$127.19 million

Price / Sales2.67

Cash Flow$0.58 per share

Price / Cash Flow13.06

Book Value$3.04 per share

Price / Book2.51

Profitability

EPS (Most Recent Fiscal Year)$0.55

Net Income$22.25 million

Net Margins16.87%

Return on Equity16.24%

Return on Assets13.19%

Miscellaneous

Employees408

Outstanding Shares44,520,000

Market Cap$339.69 million

Next Earnings Date8/4/2020 (Estimated)

OptionableNot Optionable

Receive KMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.

Kamada (NASDAQ:KMDA) Frequently Asked Questions

How has Kamada's stock been impacted by COVID-19 (Coronavirus)?

Kamada's stock was trading at $5.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, KMDA stock has increased by 48.2% and is now trading at $7.63. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kamada?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kamada.

When is Kamada's next earnings date?

Kamada is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Kamada.

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) posted its earnings results on Wednesday, February, 12th. The biotechnology company reported $0.13 EPS for the quarter, hitting the Thomson Reuters' consensus estimate of $0.13. The biotechnology company earned $32.07 million during the quarter, compared to analyst estimates of $31.63 million. Kamada had a net margin of 16.87% and a return on equity of 16.24%. View Kamada's earnings history.

What guidance has Kamada issued on next quarter's earnings?

Kamada issued an update on its FY 2020 Pre-Market earnings guidance on Monday, May, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $132-137 million, compared to the consensus revenue estimate of $134.76 million.

What price target have analysts set for KMDA?

1 brokerages have issued 12-month target prices for Kamada's stock. Their forecasts range from $11.00 to $11.00. On average, they expect Kamada's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 44.2% from the stock's current price. View analysts' price targets for Kamada.

What are Wall Street analysts saying about Kamada stock?

Here are some recent quotes from research analysts about Kamada stock:

1. According to Zacks Investment Research, "Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. " (5/22/2020)
2. HC Wainwright analysts commented, "Our price target of $11/share is based on an equally weighted composite of: (a) $14.26/share, as a 35x multiple of taxed and diluted FY23 GAAP EPS of $0.84 discounted back to and (b) an NPV of $8.1/share (discount rate 12%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of AAT (IV and IH) to achieve peak commercial revenue estimates in our model (due to market size, penetration rates, and/ or pricing); (2) failure of IH-AAT in clinical studies; (3) failure of IH-AAT to secure regulatory approval; and (4) other potential pipeline failures." (8/7/2019)

Has Kamada been receiving favorable news coverage?

Media headlines about KMDA stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kamada earned a news sentiment score of 2.6 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutKamada.

Are investors shorting Kamada?

Kamada saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 74,300 shares, a decrease of 13.8% from the April 30th total of 86,200 shares. Based on an average daily volume of 83,000 shares, the short-interest ratio is currently 0.9 days. Approximately 0.3% of the company's shares are short sold. View Kamada's Current Options Chain.

Who are some of Kamada's key competitors?

Some companies that are related to Kamada include Intra-Cellular Therapies (ITCI), Mersana Therapeutics (MRSN), Arvinas (ARVN), I-Mab (ARQT), Tricida (TCDA), Supernus Pharmaceuticals (SUPN), Karyopharm Therapeutics (KPTI), Kiniksa Pharmaceuticals (KNSA), Cytokinetics (CYTK), Phathom Pharmaceuticals (PHAT), Revance Therapeutics (RVNC), Esperion Therapeutics (ESPR), Myovant Sciences (MYOV), Odonate Therapeutics (ODT) and Aimmune Therapeutics (AIMT). View all competitors.

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Zoetis (ZTS) and Micron Technology (MU).

Who are Kamada's key executives?

Kamada's management team includes the following people:

Mr. Amir London, Chief Exec. Officer (Age 50)
Mr. Chaime Orlev, Chief Financial Officer (Age 49)
Mr. Eran Nir, VP of Operations & Plant Mang. (Age 46)
Mr. David Tsur, Co-Founder & Active Deputy Chairman (Age 68)
Dr. Naveh Tov M.D., Ph.D., VP of Clinical Devel. & Medical Director for Pulmonary Diseases (Age 55)

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

Who are Kamada's major shareholders?

Kamada's stock is owned by a variety of retail and institutional investors. Top institutional investors include Phoenix Holdings Ltd. (2.32%), Meitav Dash Investments Ltd. (2.00%), Morgan Stanley (0.31%), UBS Group AG (0.17%), ETF Managers Group LLC (0.11%) and James Investment Research Inc. (0.10%).

Which institutional investors are selling Kamada stock?

KMDA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, AXA, BlackRock Inc., and Analyst IMS Investment Management Services Ltd..

Which institutional investors are buying Kamada stock?

KMDA stock was purchased by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd., James Investment Research Inc., Phoenix Holdings Ltd., Seizert Capital Partners LLC, Ritholtz Wealth Management, UBS Group AG, and ETF Managers Group LLC.

How do I buy shares of Kamada?

Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $7.63.

How big of a company is Kamada?

Kamada has a market capitalization of $339.69 million and generates $127.19 million in revenue each year. The biotechnology company earns $22.25 million in net income (profit) each year or $0.55 on an earnings per share basis. Kamada employs 408 workers across the globe.

What is Kamada's official website?

The official website for Kamada is www.kamada.com.

How can I contact Kamada?

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff